Product Registration

Workflow steps

1. Product for NZ Market
   Product intended for the New Zealand market. Products must meet MQS standards and receive MCA product approval under the NZMCS. CBD products have a simpler pathway. Section 29 pathway also available for unapproved medicines.
2. MCA Product Approval — NZMCS assessment
   MCA assesses products against the Minimum Quality Standard (MQS) under the NZ Medicinal Cannabis Scheme. CBD products have a simpler pathway with reduced requirements.
   • Product specifications meet MQS standards
   • GMP certificate from recognized authority
   • Analytical testing data
   • CBD products: simpler pathway with reduced requirements
3. Approved?
   MCA evaluates product against MQS. If not approved, Section 29 pathway is also available for unapproved medicines — any doctor can prescribe.
4. Section 29 Pathway — Unapproved medicines
   Section 29 of the Medicines Act provides an alternative pathway for unapproved medicines. Any doctor can prescribe under Section 29. No MCA product approval needed.
   • Any doctor can prescribe under Section 29
   • No MCA product approval required
   • Patient-specific prescription
   • Pharmacy can dispense Section 29 products
5. Product Approved ✓
   Product approved under NZMCS. Available for prescribing and dispensing through pharmacies across New Zealand.